DOCSLIB.ORG

H00009950-M01 規格 : [ 100 Ug ] List All

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
H00009950-M01 規格 : [ 100 Ug ] List All GOLGA5 monoclonal antibody (M01), clone 6B3 Catalog # : H00009950-M01 規格 : [ 100 ug ] List All Specification Application Image Product Mouse monoclonal antibody raised against a partial recombinant Western Blot (Cell lysate) Description: GOLGA5. Immunogen: GOLGA5 (NP_005104, 2 a.a. ~ 99 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Sequence: SWFVDLAGKAEDLLNRVDQGAATALSRKDNASNIYSKNTDYTELHQQNT DLIYQTGPKSTYISSAADNIRNQKATILAGTANVKVGSRTPVEASHPVE enlarge Western Blot (Transfected Host: Mouse lysate) Reactivity: Human Isotype: IgG2a Kappa Quality Control Antibody Reactive Against Recombinant Protein. Testing: enlarge Western Blot (Recombinant protein) Sandwich ELISA (Recombinant protein) enlarge Western Blot detection against Immunogen (36.52 KDa) . ELISA Storage Buffer: In 1x PBS, pH 7.4 RNAi Knockdown (Antibody Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. validated) Instruction: MSDS: Download Datasheet: Download enlarge Applications Western Blot (Cell lysate) Page 1 of 3 2016/5/22 GOLGA5 monoclonal antibody (M01), clone 6B3 Western Blot analysis of GOLGA5 expression in K-562 ( Cat # L009V1 ). Protocol Download Western Blot (Transfected lysate) Western Blot analysis of GOLGA5 expression in transfected 293T cell line by GOLGA5 monoclonal antibody (M01), clone 6B3. Lane 1: GOLGA5 transfected lysate(83 KDa). Lane 2: Non-transfected lysate. Protocol Download Western Blot (Recombinant protein) Protocol Download Sandwich ELISA (Recombinant protein) Detection limit for recombinant GST tagged GOLGA5 is approximately 0.1ng/ml as a capture antibody. Protocol Download ELISA RNAi Knockdown (Antibody validated) Page 2 of 3 2016/5/22 Western blot analysis of GOLGA5 over-expressed 293 cell line, cotransfected with GOLGA5 Validated Chimera RNAi ( Cat # H00009950-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with GOLGA5 monoclonal antibody (M01), clone 6B3 (Cat # H00009950-M01 ). GAPDH ( 36.1 kDa ) used as specificity and loading control. Protocol Download Gene Information Entrez GeneID: 9950 GeneBank NM_005113 Accession#: Protein NP_005104 Accession#: Gene Name: GOLGA5 Gene Alias: GOLIM5,RFG5,ret-II Gene golgi autoantigen, golgin subfamily a, 5 Description: Omim ID: 188550, 606918 Gene Ontology: Hyperlink Gene Summary: The Golgi apparatus, which participates in glycosylation and transport of proteins and lipids in the secretory pathway, consists of a series of stacked cisternae (flattened membrane sacs). Interactions between the Golgi and microtubules are thought to be important for the reorganization of the Golgi after it fragments during mitosis. This gene encodes a member of the golgin family of proteins, whose members localize to the Golgi. This protein is a coiled-coil membrane protein that has been postulated to play a role in vesicle tethering and docking. Translocations involving this gene and the ret proto-oncogene have been found in tumor tissues; the chimeric sequences have been designated RET-II and PTC5. [provided by RefSeq Other Golgi autoantigen, golgin subfamily a, 5,cell proliferation-inducing gene Designations: 31,golgi integral membrane protein 5,golgin-84,ret-fused gene 5 服務條款 | 隱私權政策 | 著作及商標 | 網站地圖 ©2016 亞諾法生技股份有限公司 Abnova Corporation. 版權所有. Page 3 of 3 2016/5/22.
Load more

Recommended publications
  • Influencers on Thyroid Cancer Onset: Molecular Genetic Basis
    G C A T T A C G G C A T genes Review Influencers on Thyroid Cancer Onset: Molecular Genetic Basis Berta Luzón-Toro 1,2, Raquel María Fernández 1,2, Leticia Villalba-Benito 1,2, Ana Torroglosa 1,2, Guillermo Antiñolo 1,2 and Salud Borrego 1,2,* 1 Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Seville, Spain; [email protected] (B.L.-T.); [email protected] (R.M.F.); [email protected] (L.V.-B.); [email protected] (A.T.); [email protected] (G.A.) 2 Centre for Biomedical Network Research on Rare Diseases (CIBERER), 41013 Seville, Spain * Correspondence: [email protected]; Tel.: +34-955-012641 Received: 3 September 2019; Accepted: 6 November 2019; Published: 8 November 2019 Abstract: Thyroid cancer, a cancerous tumor or growth located within the thyroid gland, is the most common endocrine cancer. It is one of the few cancers whereby incidence rates have increased in recent years. It occurs in all age groups, from children through to seniors. Most studies are focused on dissecting its genetic basis, since our current knowledge of the genetic background of the different forms of thyroid cancer is far from complete, which poses a challenge for diagnosis and prognosis of the disease. In this review, we describe prevailing advances and update our understanding of the molecular genetics of thyroid cancer, focusing on the main genes related with the pathology, including the different noncoding RNAs associated with the disease.
    [Show full text]
  • Genotyping of Breech Flystrike Resource – Update
    Project No: ON-00515 Contract No: PO4500010753 AWI Project Manager: Bridget Peachey Contractor Name: CSIRO Agriculture and Food Prepared by: Dr Sonja Dominik Publication Date: July 2019 Genotyping of breech flystrike resource – update Published by Australian Wool Innovation Limited, Level 6, 68 Harrington Street, THE ROCKS, NSW, 2000 This publication should only be used as a general aid and is not a substitute for specific advice. To the extent permitted by law, we exclude all liability for loss or damage arising from the use of the information in this publication. AWI invests in research, development, innovation and marketing activities along the global supply chain for Australian wool. AWI is grateful for its funding, which is primarily provided by Australian woolgrowers through a wool levy and by the Australian Government which provides a matching contribution for eligible R&D activities © 2019 Australian Wool Innovation Ltd. All rights reserved. Contents Executive Summary .................................................................................................................... 3 1 Introduction/Hypothesis .................................................................................................... 5 2 Literature Review ............................................................................................................... 6 3 Project Objectives .............................................................................................................. 8 4 Success in Achieving Objectives ........................................................................................
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia
    cancers Article The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia Jonathan Lukas Lühmann 1,† , Marie Stelter 1,†, Marie Wolter 1, Josephine Kater 1, Jana Lentes 1, Anke Katharina Bergmann 1, Maximilian Schieck 1 , Gudrun Göhring 1, Anja Möricke 2, Gunnar Cario 2, Markéta Žaliová 3 , Martin Schrappe 2, Brigitte Schlegelberger 1, Martin Stanulla 4 and Doris Steinemann 1,* 1 Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany; [email protected] (J.L.L.); [email protected] (M.S.); [email protected] (M.W.); [email protected] (J.K.); [email protected] (J.L.); [email protected] (A.K.B.); [email protected] (M.S.); [email protected] (G.G.); [email protected] (B.S.) 2 Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany; [email protected] (A.M.); [email protected] (G.C.); [email protected] (M.S.) 3 Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, CZ-15006 Prague, Czech Republic; [email protected] 4 Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany; [email protected] * Correspondence: [email protected] † These authors equally contributed to this work. Citation: Lühmann, J.L.; Stelter, M.; Wolter, M.; Kater, J.; Lentes, J.; Bergmann, A.K.; Schieck, M.; Simple Summary: The stratification of childhood ALL is currently based on various diagnostic Göhring, G.; Möricke, A.; Cario, G.; assays.
    [Show full text]
  • GOLGA5 Purified Maxpab Rabbit Polyclonal Antibody (D01P)
    GOLGA5 purified MaxPab rabbit polyclonal antibody (D01P) Catalog # : H00009950-D01P 規格 : [ 100 ug ] List All Specification Application Image Product Rabbit polyclonal antibody raised against a full-length human GOLGA5 Western Blot (Tissue lysate) Description: protein. Immunogen: GOLGA5 (NP_005104.2, 1 a.a. ~ 731 a.a) full-length human protein. Sequence: MSWFVDLAGKAEDLLNRVDQGAATALSRKDNASNIYSKNTDYTELHQQN TDLIYQTGPKSTYISSAADNIRNQKATILAGTANVKVGSRTPVEASHPVEN enlarge ASVPRPSSHFVRRKKSEPDDELLFDFLNSSQKEPTGRVEIRKEKGKTPV FQSSQTSSVSSVNPSVTTIKTIEENSFGSQTHEAASNSDSSHEGQEESSK Western Blot (Tissue lysate) ENVSSNAACPDHTPTPNDDGKSHELSNLRLENQLLRNEVQSLNQEMASL LQRSKETQEELNKARARVEKWNADHSKSDRMTRGLRAQVDDLTEAVAA KDSQLAVLKVRLQEADQLLSTRTEALEALQSEKSRIMQDQSEGNSLQNQ ALQTFQERLHEADATLKREQESYKQMQSEFAARLNKVEMERQNLAEAIT LAERKYSDEKKRVDELQQQVKLYKLNLESSKQELIDYKQKATRILQSKEK LINSLKEGSGFEGLDSSTASSMELEELRHEKEMQREEIQKLMGQIHQLRS ELQDMEAQQVNEAESAREQLQDLHDQIAGQKASKQELETELERLKQEF HYIEEDLYRTKNTLQSRIKDRDEEIQKLRNQLTNKTLSNSSQSELENRLHQ enlarge LTETLIQKQTMLESLSTEKNSLVFQLERLEQQMNSASGSSSNGSSINMSG IDNGEGTRLRNVPVLFNDTETNLAGMYGKVRKAASSIDQFSIRLGIFLRRY Western Blot (Cell lysate) PIARVFVIIYMALLHLWVMIVLLTYTPEMHHDQPYGK Host: Rabbit Reactivity: Human, Mouse enlarge Quality Control Antibody reactive against mammalian transfected lysate. Testing: Western Blot (Transfected lysate) Storage Buffer: In 1x PBS, pH 7.4 Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Instruction: MSDS: Download enlarge Datasheet: Download Immunofluorescence Applications Western Blot (Tissue lysate)
    [Show full text]
  • Table 2. All Probe Sets with Fold Changes Higher Than Set Thresholds but P > 0.001 Affy No
    Supporting information for Sanoudou et al. (2003) Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0330960100 Table 2. All probe sets with fold changes higher than set thresholds but P > 0.001 Affy no. Gene name Symbol Location Fold Down-regulated probe sets 47879_at N46863 -16.9 59447_at N52773 -9.6 55503_at AI085361 -9.1 47087_at AI310524 -9.0 37209_g_at phosphoserine phosphatase-like PSPHL 7q11.2 -8.4 47137_at AI479899 19p13.3 -8.1 45876_at AA536137 -6.9 45260_at TU3A protein TU3A 3p21.1 -6.7 56246_at 6-phosphofructo-2-kinase/fructose-2,6- PFKFB3 10p14-p15 -6.7 bisphosphatase 3 50230_at hexokinase 2 HK2 2p13 -6.6 38248_at AB011124 20p13 -6.5 44426_at R93141 -6.4 48542_at W27559 -6.3 53813_at AW051518 13q13.3 -6.1 59577_at AA243670 -6.0 46907_at W37075 -5.8 49078_at AA424983 -5.7 49026_at AI357153 20p12.3 -5.4 53487_at AI670947 -5.4 50161_at N39328 -5.1 35994_at AC002398 F25965 19q13.1 -4.9 52285_f_at AW002970 18p11.1 -4.8 40964_at hexokinase 2 HK2 2p13 -4.6 49806_at AI932283 -4.5 58918_at molecule possessing ankyrin repeats induced by MAIL 3p12-q12 -4.3 lipopolysaccharide (MAIL), homolog of mouse 44633_at heat shock 27 kDa associated protein 3q21.1 -4.3 46858_at AI796221 -4.2 36711_at v-maf musculoaponeurotic fibrosarcoma oncogene MAFF 22q13.1 -4.1 homolog F (avian) 54683_at N49844 -4.1 46621_at N32595 -4.1 49629_at N47713 -3.9 47703_at W89189 -3.9 59313_at AI598222 -3.8 34721_at FK506 binding protein 5 FKBP5 6p21.3-21.2 -3.8 46843_at AI632621 -3.7 59611_at R53069 16p11.2 -3.7 58315_at AA778171 3p25.1 -3.6 46607_f_at AI885018 17q25.3 -3.6 33143_s_at solute carrier family 16 (monocarboxylic acid SLC16A3 22q12.3-q13.2 -3.5 transporters), member 3 54152_at eukaryotic translation initiation factor 4E binding EIF4EBP1 8p12 -3.4 protein 1 43935_at ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin ARAP3 5q31.3 -3.2 homology domains-containing protein 3 33849_at pre-B-cell colony-enhancing factor PBEF 7q11.23 -3.2 46902_at N92294 -3.2 47023_at N25555 -3.1 Page 1 of 14 Supporting information for Sanoudou et al.
    [Show full text]
  • 1 Novel Expression Signatures Identified by Transcriptional Analysis
    ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009.
    [Show full text]
  • Kinase Fusions Are Frequent in Spitz Tumours and Spitzoid Melanomas
    ARTICLE Received 25 Sep 2013 | Accepted 15 Dec 2013 | Published 20 Jan 2014 DOI: 10.1038/ncomms4116 Kinase fusions are frequent in Spitz tumours and spitzoid melanomas Thomas Wiesner1,2,*, Jie He3,*, Roman Yelensky3,*, Rosaura Esteve-Puig4, Thomas Botton4,IweiYeh4, Doron Lipson3, Geoff Otto3, Kristina Brennan3, Rajmohan Murali5,6, Maria Garrido4, Vincent A. Miller3, Jeffrey S. Ross3, Michael F. Berger1, Alyssa Sparatta4, Gabriele Palmedo7, Lorenzo Cerroni2, Klaus J. Busam5, Heinz Kutzner7, Maureen T. Cronin3, Philip J. Stephens3 & Boris C. Bastian1,4,5 Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features. They include benign tumours (Spitz naevi), malignant tumours (spitzoid melano- mas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours). Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent. Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern. The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas. Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro. In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas. 1 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 415 E 68th Street, New York, New York 10065, USA. 2 Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria.
    [Show full text]
  • Identifying Human Interactors of SARS-Cov-2 Proteins and Drug Targets for COVID-19 Using Network-Based Label Propagation Arxiv:2
    Identifying Human Interactors of SARS-CoV-2 Proteins and Drug Targets for COVID-19 using Network-Based Label Propagation Jeffrey N. Law1, Kyle Akers1, Nure Tasnina2, Catherine M. Della Santina3, Meghana Kshirsagar4, Judith Klein-Seetharaman5, Mark Crovella6, Padmavathy Rajagopalan7, Simon Kasif3, and T. M. Murali2,* 1Interdisciplinary Ph.D. Program in Genetics, Bioinformatics, and Computational Biology, Blacksburg, VA, USA 2Department of Computer Science, Virginia Tech, Blacksburg, VA, USA 3Department of Biomedical Engineering, Boston University, Boston, MA, USA 4AI for Good Lab, Microsoft, Redmond, WA, USA 5Department of Chemistry, Colorado School of Mines, Golden, CO USA 6Department of Computer Science, Boston University, Boston, MA, USA 7Department of Chemical Engineering, Virginia Tech, Blacksburg, VA, USA *Corresponding author. Email: [email protected] Motivated by the critical need to identify new treatments for COVID- arXiv:2006.01968v2 [q-bio.MN] 22 Jun 2020 19, we present a genome-scale, systems-level computational approach to prioritize drug targets based on their potential to regulate host- virus interactions or their downstream signaling targets. We adapt and specialize network label propagation methods to this end. We demonstrate that these techniques can predict human-SARS-CoV- 2 protein interactors with high accuracy. The top-ranked proteins 1 that we identify are enriched in host biological processes that are po- tentially coopted by the virus. We present cases where our method- ology generates promising insights such as the potential role of HSPA5 in viral entry. We highlight the connection between en- doplasmic reticulum stress, HSPA5, and anti-clotting agents. We identify tubulin proteins involved in ciliary assembly that are tar- geted by anti-mitotic drugs.
    [Show full text]
  • Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs
    cancers Article Molecular Characterization of Astrocytoma Progression Towards Secondary Glioblastomas Utilizing Patient-Matched Tumor Pairs Michael Seifert 1,2,* , Gabriele Schackert 2,3,4, Achim Temme 2,3,4, Evelin Schröck 2,4,5,6,7, Andreas Deutsch 8 and Barbara Klink 2,4,5,9 1 Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, D-01307 Dresden, Germany 2 National Center for Tumor Diseases (NCT), Partner Site Dresden, D-01307 Dresden, Germany; [email protected] (G.S.); [email protected] (A.T.); [email protected] (E.S.); [email protected] (B.K.) 3 Department of Neurosurgery, Section Experimental Neurosurgery/Tumor Immunology, University Hospital Carl Gustav Carus, Technische Universität Dresden, D-01307 Dresden, Germany 4 German Cancer Consortium (DKTK), Dresden, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany 5 Institute for Clinical Genetics, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, D-01307 Dresden, Germany 6 ERN-GENTURIS, Hereditary Cancer Syndrome Center Dresden, D-01307 Dresden, Germany 7 Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), D-01307 Dresden, Germany 8 Center for Information Services and High Performance Computing (ZIH), Technische Universität Dresden, D-01062 Dresden, Germany; [email protected] 9 National Center of Genetics (NCG), Laboratoire national de santé (LNS), L-3555 Dudelange, Luxembourg * Correspondence: [email protected] Received: 19 May 2020; Accepted: 21 June 2020; Published: 26 June 2020 Abstract: Astrocytomas are primary human brain tumors including diffuse or anaplastic astrocytomas that develop towards secondary glioblastomas over time.
    [Show full text]
  • Molecular Network of Collagen, Type III, Alpha-1 at the Gene Expression Level: Obstacles That Translational Research Must Overcome
    Int. J. Mol. Sci. 2015, 16, 15031-15056; doi:10.3390/ijms160715031 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Differences between Mice and Humans in Regulation and the Molecular Network of Collagen, Type III, Alpha-1 at the Gene Expression Level: Obstacles that Translational Research Must Overcome Lishi Wang 1,2, Hongchao Liu 3, Yan Jiao 1,4, Erjian Wang 3, Stephen H. Clark 5, Arnold E. Postlethwaite 6,7, Weikuan Gu 1,7,* and Hong Chen 3,* 1 Department of Orthopedic Surgery and BME-Campbell Clinic, University of Tennessee Health Science Center, Memphis, TN 38163, USA; E-Mails: [email protected] (L.W.); [email protected] (Y.J.) 2 Department of Basic Research, Inner Mongolia Medical College, Inner Mongolia 010110, China 3 Integrative Research Center, the first Hospital of Qiqihaer City, Qiqihaer 161005, China; E-Mails: [email protected] (H.L.); [email protected] (E.W.) 4 Department of Medicine, Mudanjiang Medical College, Mudanjiang 157001, China 5 Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT 06030, USA; E-Mail: [email protected] 6 Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; E-Mail: [email protected] 7 Research Service, Veterans Affairs Medical Center, Memphis, TN 38104, USA * Authors to whom correspondence should be addressed; E-Mails: [email protected] (W.G.); [email protected] (H.C.); Tel.: +01-901-448-2258 (W.G.); +86-452-242-5981 (H.C.); Fax: +01-901-448-6062 (W.G.); +86-452-247-0942 (H.C.).
    [Show full text]
  • Table S1: Gene Symbol Full Gene Name Entrez Gene ID Refseq A2M
    Table S1: Gene Symbol Full Gene Name Entrez Gene ID RefSeq A2M alpha-2-macroglobulin 2 NM_000014 ABHD15 abhydrolase domain containing 15 116236 NM_198147 ACADVL acyl-Coenzyme A dehydrogenase, very long chain 37 NM_000018 ACSS1 acyl-CoA synthetase short-chain family member 1 84532 NM_032501 ACY3 aspartoacylase (aminocyclase) 3 91703 NM_080658 ADAM33 ADAM metallopeptidase domain 33 80332 NM_153202 AFF2 AF4/FMR2 family, member 2 2334 NM_002025 ALX1 ALX homeobox 1 8092 NM_006982 ANGPTL4 angiopoietin-like 4 51129 NM_001039667 ANKRD20A3 ankyrin repeat domain 20 family, member A3 441425 NM_001012419 ANKRD45 ankyrin repeat domain 45 339416 NM_198493 ANXA1 annexin A1 301 NM_000700 ANXA5 annexin A5 308 NM_001154 APBB1IP amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 54518 NM_019043 ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 64411 NM_022481 ARF3 ADP-ribosylation factor 3 377 NM_001659 ARF5 ADP-ribosylation factor 5 381 NM_001662 ARHGAP1 Rho GTPase activating protein 1 392 NM_004308 ARHGAP6 Rho GTPase activating protein 6 395 NM_006125 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 396 NM_004309 ARMC8 armadillo repeat containing 8 25852 NM_014154 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 488 NM_170665 ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 10159 NM_005765 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 526 NM_001693 B3GNT8 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 374907 NM_198540 B4GALNT1 beta-1,4-N-acetyl-galactosaminyl
    [Show full text]